CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 40

CardioVascular BioTherapeutics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CardioVascular BioTherapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CardioVascular BioTherapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CardioVascular BioTherapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CardioVascular BioTherapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CardioVascular BioTherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CardioVascular BioTherapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CardioVascular BioTherapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CardioVascular BioTherapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CardioVascular BioTherapeutics, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
CardioVascular BioTherapeutics, Inc. Snapshot
CardioVascular BioTherapeutics, Inc. Overview
Key Information
Key Facts
CardioVascular BioTherapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
CardioVascular BioTherapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CardioVascular BioTherapeutics, Inc. – Pipeline Products Glance
CardioVascular BioTherapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CardioVascular BioTherapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
CardioVascular BioTherapeutics, Inc. – Drug Profiles
CVBT-141A
Product Description
Mechanism of Action
R&D Progress
CVBT-141H
Product Description
Mechanism of Action
R&D Progress
CVBT-141B
Product Description
Mechanism of Action
R&D Progress
CVBT-141C
Product Description
Mechanism of Action
R&D Progress
CVBT-141F
Product Description
Mechanism of Action
R&D Progress
CVBT-141G
Product Description
Mechanism of Action
R&D Progress
CardioVascular BioTherapeutics, Inc. – Pipeline Analysis
CardioVascular BioTherapeutics, Inc. – Pipeline Products by Therapeutic Class
CardioVascular BioTherapeutics, Inc. Pipeline Products By Target
CardioVascular BioTherapeutics, Inc. – Pipeline Products by Route of Administration
CardioVascular BioTherapeutics, Inc. – Company Statement
CardioVascular BioTherapeutics, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 25, 2008: CardioVascular BioTherapeutics Initiates Phase II Clinical Trial Of CVBT-141H For Severe Coronary Heart Disease
Oct 02, 2007: CardioVascular BioTherapeutics Completes Phase I Trial Of CVBT-141B For Diabetic
Jul 12, 2007: CardioVascular BioTherapeutics Announces Preclinical Study Results
Financial Deals Landscape
CardioVascular BioTherapeutics, Inc., Deals Volume Summary, 2004 to YTD 2010
CardioVascular BioTherapeutics, Inc., Deals Summary By Region, 2004 to YTD 2010
CardioVascular BioTherapeutics, Inc., Deals Summary, 2004 to YTD 2010
CardioVascular BioTherapeutics, Inc. Detailed Deal Summary
Equity Offering
CardioVascular BioTherapeutics Completes Private Placement Of $15 Million
CardioVascular BioTherapeutics Completes Initial Public Offering Of $17 Million
Debt Offering
CardioVascular BioTherapeutics Completes Private Placement Of Senior Secured notes For $20 Million
CardioVascular BioTherapeutics Enters Into Co-Development Agreement With Cardio Neo-Genesis
Cardiovascular Biotherapeutics Forms Partnership With Phillip Frey Jr.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Journal of Social Distress and the Homeless
• The CBRN Defense Market 2013-2023